$ZLAB
Stock $zlab

$zlab Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000162828024007235 Filed on February 27, 2024

Income Statement

Concept	2023 Q4	2023
Revenue	$65.83M	$266.7M
YoY Change	5.16%	24.03%
Cost Of Revenue	$25.24M	$95.82M
YoY Change	20.61%	29.45%
Gross Profit	$40.59M	$170.9M
YoY Change	-2.6%	21.19%
Gross Profit Margin	61.66%	64.08%
Selling, General & Admin	$82.63M	$281.6M
YoY Change	14.72%	8.74%
% of Gross Profit	203.55%	164.78%
Research & Development	$81.95M	$265.9M
YoY Change	22.41%	-7.17%
% of Gross Profit	201.88%	155.57%
Depreciation & Amortization	$2.459M	$9.029M
YoY Change	15.61%	9.75%
% of Gross Profit	6.06%	5.28%
Operating Expenses	$164.6M	$547.5M
YoY Change	18.42%	0.38%
Operating Profit	-$124.0M	-$366.6M
YoY Change	27.43%	-9.34%
Interest Expense	$21.77M	$24.95M
YoY Change	-146.26%
% of Operating Profit
Other Income/Expense, Net	$6.783M	$7.006M
YoY Change	-91.79%	125.06%
Pretax Income	-$95.43M	-$334.6M
YoY Change	54.49%	-24.51%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$95.43M	-$334.6M
YoY Change	54.49%	-24.51%
Net Earnings / Revenue	-144.96%	-125.46%
Basic Earnings Per Share		-$0.35
Diluted Earnings Per Share	-$0.10	-$0.35
COMMON SHARES
Basic Shares Outstanding		966.4M shares
Diluted Shares Outstanding		966.4M shares

Balance Sheet

Concept	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$806.5M	$806.5M
YoY Change	-20.03%	-20.03%
Cash & Equivalents	$790.2M	$1.100M
Short-Term Investments	$16.30M	$16.30M
Other Short-Term Assets	$23.00M	$23.00M
YoY Change	-35.54%	-35.54%
Inventory	$44.83M	$44.83M
Prepaid Expenses
Receivables	$59.20M	$59.20M
Other Receivables	$6.134M	$6.134M
Total Short-Term Assets	$939.6M	$939.6M
YoY Change	-16.43%	-16.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$53.73M	$68.58M
YoY Change	-7.14%	-11.37%
Goodwill
YoY Change
Intangibles	$13.39M
YoY Change	786.1%
Long-Term Investments	$9.220M	$9.220M
YoY Change	43.37%	43.37%
Other Assets	$2.433M	$2.433M
YoY Change	-32.32%	-32.32%
Total Long-Term Assets	$96.69M	$96.69M
YoY Change	0.92%	0.92%
TOTAL ASSETS
Total Short-Term Assets	$939.6M	$939.6M
Total Long-Term Assets	$96.69M	$96.69M
Total Assets	$1.036B	$1.036B
YoY Change	-15.07%	-15.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$113.0M	$113.0M
YoY Change	71.27%	71.27%
Accrued Expenses	$40.82M	$40.82M
YoY Change	5.36%	5.36%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$203.1M	$203.1M
YoY Change	45.21%	45.21%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$325.0K	$37.11M
YoY Change		6.94%
Total Long-Term Liabilities	$325.0K	$37.11M
YoY Change		6.94%
TOTAL LIABILITIES
Total Short-Term Liabilities	$203.1M	$203.1M
Total Long-Term Liabilities	$325.0K	$37.11M
Total Liabilities	$240.2M	$240.2M
YoY Change	37.6%	37.6%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.196B
YoY Change	17.98%
Common Stock	$2.975B
YoY Change	2.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$796.1M	$796.1M
YoY Change
Total Liabilities & Shareholders Equity	$1.036B	$1.036B
YoY Change	-15.07%	-15.07%

Cashflow Statement

Concept	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$95.43M	-$334.6M
YoY Change	54.49%	-24.51%
Depreciation, Depletion And Amortization	$2.459M	$9.029M
YoY Change	15.61%	9.75%
Cash From Operating Activities	-$14.92M	-$198.2M
YoY Change	-86.35%	-46.09%
INVESTING ACTIVITIES
Capital Expenditures	$843.0K	$7.212M
YoY Change	-80.72%	-70.67%
Acquisitions
YoY Change
Other Investing Activities	$15.30M	-$2.285M
YoY Change		-100.51%
Cash From Investing Activities	$14.46M	-$10.78M
YoY Change	-430.6%	-102.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	393.0K	-$6.433M
YoY Change	-297.49%	271.85%
NET CHANGE
Cash From Operating Activities	-14.92M	-$198.2M
Cash From Investing Activities	14.46M	-$10.78M
Cash From Financing Activities	393.0K	-$6.433M
Net Change In Cash	-67.00K	-$218.0M
YoY Change	-99.94%	-591.34%
FREE CASH FLOW
Cash From Operating Activities	-$14.92M	-$198.2M
Capital Expenditures	$843.0K	$7.212M
Free Cash Flow	-$15.76M	-$205.4M
YoY Change	-86.13%	-47.63%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001704292
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38205
CY2023	dei	Entity Registrant Name EntityRegistrantName	ZAI LAB LIMITED
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1144595
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	4560 Jinke Road
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Bldg. 1, Fourth Floor Pudong
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Shanghai
CY2023	dei	Entity Address Country EntityAddressCountry	CN
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	201210
CY2023	dei	City Area Code CityAreaCode	86 21
CY2023	dei	Local Phone Number LocalPhoneNumber	6163 2588
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	2700000000	usd
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	185
CY2021	dei	Auditor Firm AuditorFirmId	1113
CY2023	dei	Auditor Name AuditorName	KPMG LLP
CY2023	dei	Auditor Location AuditorLocation	Short Hills, New Jersey
CY2021	dei	Auditor Name AuditorName	Deloitte Touche Tohmatsu Certified Public Accountants LLP
CY2021	dei	Auditor Location AuditorLocation	Shanghai, the People’s Republic of China
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	790151000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1008470000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	16300000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	17000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	11000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	59199000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	39963000	usd
CY2023Q4	us-gaap	Financing Receivable Excluding Accrued Interest After Allowance For Credit Loss Current FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossCurrent	6134000	usd
CY2022Q4	us-gaap	Financing Receivable Excluding Accrued Interest After Allowance For Credit Loss Current FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossCurrent	8608000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	44827000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	31621000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	22995000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	35674000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	939606000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1124336000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1113000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	803000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	9220000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	6431000	usd
CY2023Q4	zlab	Prepayments For Equipment PrepaymentsForEquipment	111000	usd
CY2022Q4	zlab	Prepayments For Equipment PrepaymentsForEquipment	1396000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	53734000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57863000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	14844000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19512000	usd
CY2023Q4	zlab	Land Use Rights Net Noncurrent LandUseRightsNetNoncurrent	3069000	usd
CY2022Q4	zlab	Land Use Rights Net Noncurrent LandUseRightsNetNoncurrent	6892000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	13389000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1511000	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	1209000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	1396000	usd
CY2023Q4	us-gaap	Assets Assets	1036295000	usd
CY2022Q4	us-gaap	Assets Assets	1220140000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	112991000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	65974000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7104000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7050000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	82972000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	66818000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	203067000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	139842000	usd
CY2023Q4	us-gaap	Deferred Income Noncurrent DeferredIncomeNoncurrent	28738000	usd
CY2022Q4	us-gaap	Deferred Income Noncurrent DeferredIncomeNoncurrent	21360000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8047000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13343000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	325000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	usd
CY2023Q4	us-gaap	Liabilities Liabilities	240177000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	174545000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000006
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000006
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	977151270	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	962455850	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	972239070	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	960219570	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2975302000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2893120000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2195980000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1861360000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	37626000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	25685000	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4912200	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2236280	shares
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	20836000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	11856000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	796118000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1045595000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1036295000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1220140000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	266719000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	212672000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	144105000	usd
CY2023	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	0	usd
CY2022	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	2368000	usd
CY2021	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	207000	usd
CY2023	us-gaap	Revenues Revenues	266719000	usd
CY2022	us-gaap	Revenues Revenues	215040000	usd
CY2021	us-gaap	Revenues Revenues	144312000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	95816000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	74018000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	52239000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	265868000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	286408000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	573306000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	281608000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	258971000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	218831000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	10000000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	usd
CY2021	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-366573000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-404357000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-700064000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	39797000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	14582000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	2190000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-334620000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-443065000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-703414000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-221000	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1057000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	966394130	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	966394130	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	958067140	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-334620000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-443286000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-704471000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	0	usd
CY2021	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	0	usd
CY2023	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	0	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	11941000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	49330000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-9121000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-322679000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-393956000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-713592000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1169345000	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7417000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	839000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	818036000	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	62250000	usd
CY2021	zlab	Issuance Cost Adjustment IssuanceCostAdjustment	65000	usd
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	4279000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	40714000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-704471000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-9121000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1379956000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5870000	usd
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	7577000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	61302000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-443286000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	49330000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1045595000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2548000	usd
CY2023	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	8980000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	79634000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-334620000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	11941000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	796118000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-334620000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-443286000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-704471000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	6000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	10000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	973000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	477000	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	1368000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9029000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8227000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6487000	usd
CY2023	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	57000	usd
CY2022	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2021	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2023	zlab	Amortization Of Deferred Income AmortizationOfDeferredIncome	-3383000	usd
CY2022	zlab	Amortization Of Deferred Income AmortizationOfDeferredIncome	-2602000	usd
CY2021	zlab	Amortization Of Deferred Income AmortizationOfDeferredIncome	-521000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	79634000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	61302000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	40714000	usd
CY2023	zlab	Noncash Research And Development Expenses NoncashResearchAndDevelopmentExpenses	0	usd
CY2022	zlab	Noncash Research And Development Expenses NoncashResearchAndDevelopmentExpenses	0	usd
CY2021	zlab	Noncash Research And Development Expenses NoncashResearchAndDevelopmentExpenses	62250000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-221000	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1057000	usd
CY2023	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	2789000	usd
CY2022	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-8952000	usd
CY2021	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-14617000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-159000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-560000	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-29000	usd
CY2023	zlab	Gain Loss On Disposal Of Land Use Rights GainLossOnDisposalOfLandUseRights	408000	usd
CY2022	zlab	Gain Loss On Disposal Of Land Use Rights GainLossOnDisposalOfLandUseRights	0	usd
CY2021	zlab	Gain Loss On Disposal Of Land Use Rights GainLossOnDisposalOfLandUseRights	0	usd
CY2023	zlab	Non Cash Lease Expenses NonCashLeaseExpenses	8708000	usd
CY2022	zlab	Non Cash Lease Expenses NonCashLeaseExpenses	8350000	usd
CY2021	zlab	Non Cash Lease Expenses NonCashLeaseExpenses	6119000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	10000000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	usd
CY2021	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-14850000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-56403000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	10679000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	20040000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4330000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	42319000	usd
CY2023	us-gaap	Increase Decrease In Notes Receivable Current IncreaseDecreaseInNotesReceivableCurrent	-2352000	usd
CY2022	us-gaap	Increase Decrease In Notes Receivable Current IncreaseDecreaseInNotesReceivableCurrent	1976000	usd
CY2021	us-gaap	Increase Decrease In Notes Receivable Current IncreaseDecreaseInNotesReceivableCurrent	7335000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14907000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	15382000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-12246000	usd
CY2021	zlab	Increase Decrease In Long Term Deposits IncreaseDecreaseInLongTermDeposits	8000	usd
CY2023	zlab	Increase Decrease In Value Added Taxes Receivable IncreaseDecreaseInValueAddedTaxesReceivable	0	usd
CY2022	zlab	Increase Decrease In Value Added Taxes Receivable IncreaseDecreaseInValueAddedTaxesReceivable	-22781000	usd
CY2021	zlab	Increase Decrease In Value Added Taxes Receivable IncreaseDecreaseInValueAddedTaxesReceivable	1717000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	36803000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-53773000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	63522000	usd
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	19810000	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	7392000	usd
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	30142000	usd
CY2023	zlab	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-8351000	usd
CY2022	zlab	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-8455000	usd
CY2021	zlab	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-5385000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	11181000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1379000	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	11149000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	325000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-198178000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-367642000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-549231000	usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	134000000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	260274000	usd
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	445000000	usd
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	117700000	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	705274000	usd
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	743902000	usd
CY2023	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	usd
CY2022	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	usd
CY2021	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	30000000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7212000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24585000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18295000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	122000	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1279000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	399000	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	653000	usd
CY2023	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	10000000	usd
CY2022	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	0	usd
CY2021	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	0	usd
CY2023	zlab	Proceeds From Disposal Of Land Use Rights ProceedsFromDisposalOfLandUseRights	3893000	usd
CY2022	zlab	Proceeds From Disposal Of Land Use Rights ProceedsFromDisposalOfLandUseRights	0	usd
CY2021	zlab	Proceeds From Disposal Of Land Use Rights ProceedsFromDisposalOfLandUseRights	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10776000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	420016000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	249957000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2369000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5870000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7417000	usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	818875000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1837000	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	8802000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	7600000	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	4253000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-6433000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1730000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	820202000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-2622000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-6274000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1116000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-218009000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	44370000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	522044000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1009273000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	964903000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	442859000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	791264000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1009273000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	964903000	usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	2474000	usd
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	5269000	usd
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	2568000	usd
CY2023	zlab	Non Cash Payables For Intangible Assets NonCashPayablesForIntangibleAssets	11516000	usd
CY2022	zlab	Non Cash Payables For Intangible Assets NonCashPayablesForIntangibleAssets	163000	usd
CY2021	zlab	Non Cash Payables For Intangible Assets NonCashPayablesForIntangibleAssets	191000	usd
CY2023	zlab	Non Cash Payables For Treasury Stock NonCashPayablesForTreasuryStock	0	usd
CY2022	zlab	Non Cash Payables For Treasury Stock NonCashPayablesForTreasuryStock	2000	usd
CY2021	zlab	Non Cash Payables For Treasury Stock NonCashPayablesForTreasuryStock	26000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3668000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	14801000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2183000	usd
CY2023	zlab	Receivable Recognized For Disposal Of Property And Equipment ReceivableRecognizedForDisposalOfPropertyAndEquipment	0	usd
CY2022	zlab	Receivable Recognized For Disposal Of Property And Equipment ReceivableRecognizedForDisposalOfPropertyAndEquipment	64000	usd
CY2021	zlab	Receivable Recognized For Disposal Of Property And Equipment ReceivableRecognizedForDisposalOfPropertyAndEquipment	0	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	790151000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1008470000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	964100000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1113000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	803000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	803000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	964903000	usd
CY2022Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	10
CY2022Q1	zlab	Common Stock Authorized Share Capital CommonStockAuthorizedShareCapital	30000	usd
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000006
CY2022Q1	zlab	American Depositary Share To Common Stock Conversion Ratio AmericanDepositaryShareToCommonStockConversionRatio	1
CY2022Q1	zlab	American Depositary Share To Common Stock Conversion Ratio AmericanDepositaryShareToCommonStockConversionRatio	10
CY2023	us-gaap	Use Of Estimates UseOfEstimates	Use of Estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, accrual of rebates, recognition of research and development expenses to the appropriate financial reporting period based on actual services performed, fair value of share-based compensation expenses, and recoverability of deferred tax assets. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Actual results could differ from these estimates.
CY2023Q4	us-gaap	Financing Receivable Allowance For Credit Loss Excluding Accrued Interest Current FinancingReceivableAllowanceForCreditLossExcludingAccruedInterestCurrent	0	usd
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Loss Excluding Accrued Interest Current FinancingReceivableAllowanceForCreditLossExcludingAccruedInterestCurrent	0	usd
CY2019	zlab	Land Use Rights Lease Term LandUseRightsLeaseTerm	P30Y
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	700000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3100000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2900000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2700000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2500000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2300000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Concentration of Credit Risk </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Financial instruments that are potentially subject to significant concentration of credit risk consist of cash and cash equivalents, short-term investments, accounts receivable, and notes receivable. </span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The carrying amounts of cash and cash equivalents and short-term investments represent the maximum amount of loss due to credit risk. As of December 31, 2023 and 2022, all of the Company’s cash and cash equivalents and short-term investments were held by major financial institutions located in mainland China and international financial institutions outside of mainland China which management believes are of high credit quality and continually monitors the credit worthiness of these financial institutions.</span></div>Accounts receivable are typically unsecured and are derived from product sales and collaborative arrangements. The Company manages credit risk of accounts receivable through ongoing monitoring of the outstanding balances and limits the amount of credit extended based upon payment history and credit worthiness. Historically, the Company has collected receivables from customers within the credit terms with no significant credit losses incurred. <div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Certain accounts receivable balances may be settled in the form of notes receivable. As of December 31, 2023, notes receivable represented bank acceptance promissory notes that are non-interest bearing and due within six months. Notes receivable were used to collect the receivables based on an administrative convenience, given these notes are readily </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">convertible to be known amounts of cash. In accordance with the sales agreements, whether to use cash or bank acceptance promissory notes to settle the receivables is at the Company’s discretion, and this selection does not impact the agreed contractual purchase prices. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">Foreign Currency Risk </span></div>RMB is not a freely convertible currency. The State Administration of Foreign Exchange, under the authority of the People’s Bank of China, controls the conversion of RMB into foreign currencies. The value of RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market.
CY2023Q4	us-gaap	Cash Cash	789051000	usd
CY2022Q4	us-gaap	Cash Cash	1007423000	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	1100000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	1047000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	790151000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1008470000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	790151000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1008470000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1100000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	800000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	16300000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2023Q4	us-gaap	Debt Securities Held To Maturity Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesHeldToMaturityAllowanceForCreditLossExcludingAccruedInterest	0	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	22702000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	12156000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	17655000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	19029000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4470000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	436000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	44827000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	31621000	usd
CY2023	us-gaap	Production Related Impairments Or Charges ProductionRelatedImpairmentsOrCharges	1000000.0	usd
CY2022	us-gaap	Production Related Impairments Or Charges ProductionRelatedImpairmentsOrCharges	500000	usd
CY2021	us-gaap	Production Related Impairments Or Charges ProductionRelatedImpairmentsOrCharges	1400000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	83870000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	79927000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	30136000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	22064000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	53734000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57863000	usd
CY2023	us-gaap	Depreciation Depreciation	8400000	usd
CY2022	us-gaap	Depreciation Depreciation	7700000	usd
CY2021	us-gaap	Depreciation Depreciation	6000000.0	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	8691000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	8774000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	6263000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	9317000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	8084000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	5840000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3668000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	14801000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2183000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	7444000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5143000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1811000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	822000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	391000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	15611000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	460000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	15151000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y6M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M6D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.030
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.034
CY2023	zlab	Revenue From Contract With Customers Excluding Assessed Tax Before Adjustments For Rebates And Sales Returns RevenueFromContractWithCustomersExcludingAssessedTaxBeforeAdjustmentsForRebatesAndSalesReturns	298911000	usd
CY2022	zlab	Revenue From Contract With Customers Excluding Assessed Tax Before Adjustments For Rebates And Sales Returns RevenueFromContractWithCustomersExcludingAssessedTaxBeforeAdjustmentsForRebatesAndSalesReturns	234009000	usd
CY2021	zlab	Revenue From Contract With Customers Excluding Assessed Tax Before Adjustments For Rebates And Sales Returns RevenueFromContractWithCustomersExcludingAssessedTaxBeforeAdjustmentsForRebatesAndSalesReturns	190180000	usd
CY2023	zlab	Revenue From Contract With Customers Excluding Assessed Tax Adjustments For Rebates And Sales Returns RevenueFromContractWithCustomersExcludingAssessedTaxAdjustmentsForRebatesAndSalesReturns	32192000	usd
CY2022	zlab	Revenue From Contract With Customers Excluding Assessed Tax Adjustments For Rebates And Sales Returns RevenueFromContractWithCustomersExcludingAssessedTaxAdjustmentsForRebatesAndSalesReturns	21337000	usd
CY2021	zlab	Revenue From Contract With Customers Excluding Assessed Tax Adjustments For Rebates And Sales Returns RevenueFromContractWithCustomersExcludingAssessedTaxAdjustmentsForRebatesAndSalesReturns	46075000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	266719000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	212672000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	144105000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	266719000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	212672000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	144105000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-334620000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-443286000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-704471000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	131000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	98000	usd
CY2023Q4	zlab	Deferred Tax Assets Research And Experimental Capitalization DeferredTaxAssetsResearchAndExperimentalCapitalization	30429000	usd
CY2022Q4	zlab	Deferred Tax Assets Research And Experimental Capitalization DeferredTaxAssetsResearchAndExperimentalCapitalization	22476000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3422000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1787000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	707000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1800000	usd
CY2023Q4	zlab	Deferred Tax Assets Government Grants DeferredTaxAssetsGovernmentGrants	467000	usd
CY2022Q4	zlab	Deferred Tax Assets Government Grants DeferredTaxAssetsGovernmentGrants	189000	usd
CY2023Q4	zlab	Deferred Tax Assets Deferred Revenue DeferredTaxAssetsDeferredRevenue	4354000	usd
CY2022Q4	zlab	Deferred Tax Assets Deferred Revenue DeferredTaxAssetsDeferredRevenue	3378000	usd
CY2023Q4	zlab	Deferred Tax Assets Public Welfare Donations DeferredTaxAssetsPublicWelfareDonations	22992000	usd
CY2022Q4	zlab	Deferred Tax Assets Public Welfare Donations DeferredTaxAssetsPublicWelfareDonations	12947000	usd
CY2023Q4	zlab	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	2967000	usd
CY2022Q4	zlab	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	3738000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	295313000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	241397000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	357956000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	284072000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2826000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3738000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	2826000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	3738000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	284072000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	189684000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	73884000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	94388000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	357956000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	284072000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1804900000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1483200000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	33711000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	31689000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	7520000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4080000	usd
CY2023Q4	zlab	Payables For Purchase Of Property And Equipment Current PayablesForPurchaseOfPropertyAndEquipmentCurrent	2474000	usd
CY2022Q4	zlab	Payables For Purchase Of Property And Equipment Current PayablesForPurchaseOfPropertyAndEquipmentCurrent	5269000	usd
CY2023Q4	zlab	Accrued Rebate To Distributors Current AccruedRebateToDistributorsCurrent	16926000	usd
CY2022Q4	zlab	Accrued Rebate To Distributors Current AccruedRebateToDistributorsCurrent	8443000	usd
CY2023Q4	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	16988000	usd
CY2022Q4	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	13283000	usd
CY2023Q4	zlab	Other Payables Current Liabilities OtherPayablesCurrentLiabilities	5353000	usd
CY2022Q4	zlab	Other Payables Current Liabilities OtherPayablesCurrentLiabilities	4054000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	82972000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	66818000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-334620000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-334620000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-443286000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-443286000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-704471000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-704471000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	966394130	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	966394130	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	958067140	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	958067140	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	929921120	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	929921120	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.76
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.76
CY2023	zlab	Collaborative Arrangement Rights And Obligations Specified Royalty Term CollaborativeArrangementRightsAndObligationsSpecifiedRoyaltyTerm	P10Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	91181420	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.05
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y10M20D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	115969000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	24102740	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.36
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	6516920	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.39
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	4183190	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.68
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	104584050	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.14
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y11M19D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	83424000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	58695320	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.11
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P3Y11M4D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	83266000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	20300000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	14300000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	170400000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	79634000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	61302000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	40714000	usd
CY2023Q4	zlab	Collaborative Arrangement Rights And Obligations Maximum Additional Milestone Payments CollaborativeArrangementRightsAndObligationsMaximumAdditionalMilestonePayments	2202100000	usd
CY2023	zlab	Government Assistance Nonoperating Income GovernmentAssistanceNonoperatingIncome	2433000	usd
CY2022	zlab	Government Assistance Nonoperating Income GovernmentAssistanceNonoperatingIncome	11471000	usd
CY2021	zlab	Government Assistance Nonoperating Income GovernmentAssistanceNonoperatingIncome	4113000	usd
CY2023	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	2789000	usd
CY2022	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-8952000	usd
CY2021	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-14617000	usd
CY2023	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	1784000	usd
CY2022	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	594000	usd
CY2021	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	303000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7006000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3113000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10201000	usd

Files In Submission

Name	View Source	Status
0001628280-24-007235-index-headers.html	Edgar Link	pending
0001628280-24-007235-index.html	Edgar Link	pending
0001628280-24-007235.txt	Edgar Link	pending
0001628280-24-007235-xbrl.zip	Edgar Link	pending
ex211-subsidiarieslist2023.htm	Edgar Link	pending
ex231-consentletterfromkpmg.htm	Edgar Link	pending
ex232-consentletterfromdel.htm	Edgar Link	pending
ex971-zlabxdoddxfrankcompe.htm	Edgar Link	pending
exhibit1033-bochk_facili.htm	Edgar Link	pending
exhibit1033-bochk_facili001.jpg	Edgar Link	pending
exhibit1033-bochk_facili002.jpg	Edgar Link	pending
exhibit1033-bochk_facili003.jpg	Edgar Link	pending
exhibit1033-bochk_facili004.jpg	Edgar Link	pending
exhibit1033-bochk_facili005.jpg	Edgar Link	pending
exhibit1033-bochk_facili006.jpg	Edgar Link	pending
exhibit1033-bochk_facili007.jpg	Edgar Link	pending
exhibit1033-bochk_facili008.jpg	Edgar Link	pending
exhibit1033-bochk_facili009.jpg	Edgar Link	pending
exhibit1033-bochk_facili010.jpg	Edgar Link	pending
exhibit1033-bochk_facili011.jpg	Edgar Link	pending
exhibit1033-bochk_facili012.jpg	Edgar Link	pending
exhibit1033-bochk_facili013.jpg	Edgar Link	pending
exhibit1033-bochk_facili014.jpg	Edgar Link	pending
exhibit1033-bochk_facili015.jpg	Edgar Link	pending
exhibit1033-bochk_facili016.jpg	Edgar Link	pending
exhibit1033-bochk_facili017.jpg	Edgar Link	pending
exhibit1033-bochk_facili018.jpg	Edgar Link	pending
exhibit1033-bochk_facili019.jpg	Edgar Link	pending
exhibit1033-bochk_facili020.jpg	Edgar Link	pending
exhibit1033-bochk_facili021.jpg	Edgar Link	pending
exhibit1033-bochk_facili022.jpg	Edgar Link	pending
exhibit1033-bochk_facili023.jpg	Edgar Link	pending
exhibit1033-bochk_facili024.jpg	Edgar Link	pending
exhibit45-descriptionofsec.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
zlab-20231231.htm	Edgar Link	pending
zlab-20231231.xsd	Edgar Link	pending
zlab-20231231x10kxexx311.htm	Edgar Link	pending
zlab-20231231x10kxexx312.htm	Edgar Link	pending
zlab-20231231x10kxexx321.htm	Edgar Link	pending
zlab-20231231x10kxexx322.htm	Edgar Link	pending
zlab-20231231_g1.jpg	Edgar Link	pending
zlab-20231231_g10.jpg	Edgar Link	pending
zlab-20231231_g11.jpg	Edgar Link	pending
zlab-20231231_g12.jpg	Edgar Link	pending
zlab-20231231_g2.jpg	Edgar Link	pending
zlab-20231231_g3.jpg	Edgar Link	pending
zlab-20231231_g4.jpg	Edgar Link	pending
zlab-20231231_g5.jpg	Edgar Link	pending
zlab-20231231_g6.jpg	Edgar Link	pending
zlab-20231231_g7.jpg	Edgar Link	pending
zlab-20231231_g8.jpg	Edgar Link	pending
zlab-20231231_g9.jpg	Edgar Link	pending
zlab-20231231_lab.xml	Edgar Link	unprocessable
zlab-20231231_pre.xml	Edgar Link	unprocessable
zlab-20231231_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
zlab-20231231_cal.xml	Edgar Link	unprocessable
zlab-20231231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ZLAB
Stock $zlab

2023 Q4 Form 10-K Financial Statement

#000162828024007235 Filed on February 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZLAB Stock $zlab

2023 Q4 Form 10-K Financial Statement

#000162828024007235 Filed on February 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZLAB
Stock $zlab